Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients with Stage IV Non-Small Cell Lung Cancer

Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Jun 23, 2017

Keywords

ClinConnect Summary

The "Beating Lung Cancer in Ohio" clinical trial is investigating new treatment approaches to improve survival for patients with stage IV non-small cell lung cancer (NSCLC). This trial aims to evaluate promising therapies that could be less harmful than traditional chemotherapy and may enhance patients' quality of life. The study focuses on patients who have been diagnosed with stage IV NSCLC, including specific types like adenocarcinoma and squamous cell carcinoma, and who are current or recent smokers.

To participate, patients need to be between 65 and 74 years old, able to speak English, and willing to share their medical information. They should have a confirmed diagnosis of stage IV NSCLC or be considered likely to have it by their doctor. Participants will be asked to provide access to their medical records and may complete surveys about their health. It's important to note that patients who have already received certain treatments for lung cancer or have been in advanced treatment for over a month before joining the trial cannot participate. Through this study, patients will have the opportunity to explore new treatment options that could potentially improve their health and extend their lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • AIM 1-3
• • Pathologically confirmed stage IV NSCLC (with any Eastern Cooperative Oncology Group \[ECOG\] performance status, and any NSCLC - adenocarcinoma, squamous cell, etc.) with available imaging OR patients who do not yet have their staging completed, but in the judgment of the physician are likely to be stage IV;
• • Patients may be enrolled if the recruiter cannot reach the patient by the first office visit, preferably prior to starting therapy and no later than one month after starting therapy; (NCCN guidelines allow for a switch to targeted therapy from chemotherapy if testing comes back positive after starting chemotherapy)
• • English speaking; and
• • Willing to provide access to medical records, insurance and billing data, biospecimens and respond to questionnaires, typically by phone, but possibly to include online or in-person surveys
• • AIM 3 ONLY
• • Patients must be current smokers who smoke at least one cigarette most days per week, or recent quitters who smoked at least one cigarette most days per week (\< 3 months); and
• • Household members must be current smokers, defined as smoking at least one cigarette most days per week
• • Hearing and vision impairments that would prevent ability to complete consent, interviews, or sample collection
• Exclusion Criteria:
• • Being treated with definitive chemoradiotherapy or surgery
• • Receiving treatment for advanced lung cancer for over one month before enrollment; OR